NEWS

  • - The CombiMS project is reaching its end

    The CombiMS project is reaching its end having achieved most of its goals. Based on the predictive models developed for the pathogenic mechanism of MS, potential drug combinations to treat MS and their potential side effects, as well as biomarkers of the response to therapy, have been identified. The experimental validation of selected combination therapies, of biomarkers of response to therapy and of predicted side effects are currently undergoing and it is expected to be completed in the following weeks. In parallel, the Consortium is preparing a scientific article that will bring together the results of the projects, as well as the final project report to be submitted to the European Commission.

    16/01/2015 11:21:52
  • - Potential drug combinations to treat MS and their potential side effects have been identified

    Potential drug combinations have been identified through literature and database search and by the analysis of the MS network model generated by AX. Iterative simulations of the dynamic logic models generated by EMBL-EBI were also performed, assuming either an additive, synergistic or antagonistic effects of the drugs tested. The different drug combinations were also analysed in the different cell-specific ODE models developed by KI, using search techniques based on swarm optimization in order to extract robust predictions. Reprofiling has been carried out using the phosphoprotein data obtained from healthy and MS patients to assess the synergistic effect of drug combinations of first-line MS treatments and non-MS drugs. The alteration of the MS network models in function of the phosphoprotein data has been evaluated using different patient classifications. The phosphoprotein data has allowed the models to be customized in order to make them better reflect the real situation. Four of the drug combinations tested have shown synergism, i.e. an increase in the efficacy of the drugs alone.

    16/01/2015 11:19:51
  • - The final CombiMS meeting was held on the 17th December 2014

    The final meeting of the CombiMS Consortium was hosted by Anaxomics in Barcelona (Spain) on the 17th of December, 2014. During the meeting the members of the Consortium took stock of the work carried out during the second half of 2014 and presented their latest achievements laying down the conclusions reached by the project. Special attention was paid to the achievements of the objectives and deliverables due at the end of the project and the necessary arrangements to prepare the final report to be submitted to the European Commission. In addition, plans for the exploitation of the final results were also discussed. Based on the predictive models developed for the pathogenic mechanism of MS, potential drug combinations to treat MS and their potential side effects, as well as biomarkers of the response to therapy, have been identified, which are currently being validated. During the meeting, Fabien Richard, representative of eTRIKS and a member of the Scientific Advisory Board (SAB), provided the CombiMS consortium with his feedback on the latest results and recommendations on future activities of the consortium.

    07/01/2015 11:10:13
  • - The patient data has been successfully subjected to Logic modelling

    The normalised data obtained from healthy controls and MS patients has been used to generate a robust signalling network for each patient. Characteristic protein-protein interactions for each group of patients have been determined by the Systems Biomedicine group at EMBL-EBI (Julio Saez-Rodriguez) according to disease subtype and drug treatment. To identify an MS signalling signature associated with the disease and the response to current therapies, the patient-specific models were compared. The analysis revealed interactions that might explain the differences between the groups and the signatures of interest as therapeutic targets. (The full dataset and a comprehensive description of the normalisation process are now available to the entire consortium through the CombiMS website).

    03/10/2014 15:08:58
  • - Successful completion of the phosphoproteomic and cytokine data collection

    PAO has successfully obtained the phosphoproteomic and cytokine data from healthy controls and MS patients (xMAP assays). With this, and after filtering and curating, a robust dataset has been generated for 169 patients and healthy donors. This data was further normalised by the Systems Biomedicine group at EMBL-EBI (Julio Saez-Rodriguez) in order to be able to compare the different proteins and patient conditions, as well as opening the data to Boolean logic modelling. (The full dataset and a comprehensive description of the normalisation process are now available to the entire consortium through the CombiMS website).

    03/10/2014 15:06:41
  • - CombiMS-related work by Karolinka Institute presented at the 2014 Joint ACTRIMS-ECTRIMS Meeting

    A short talk on Genetics of MS and risk factors involved in MS pathogenesis was presented by Ingrid Kockum from the Tomas Olsson´s group (Karolinska Institute) at the 2014 Joint ACTRIMS-ECTRIMS Meeting at the John B. Hynes Veterans Memorial Convention Center in Boston (September 10-13, 2014). It was presented during the Hot Topic session on Genetics of MS that was chaired by Philip de Jager and Tomas Olsson. The abstract of the talk, titled Genetics of adult-onset MS and interaction with environmental risk factors for MS can be consulted at the following link:

    Link to original reference 12/09/2014 11:26:06
  • - CombiMS Consortium work presented at the 2nd EMBO Conference on Visualizing Biological Data (VIZBI 2014)

    A scientific poster describing the development of a mathematical model to better understand the activation mechanisms of MS, within the auspices of the CombiMS project, was presented by Marti Bernardo from the EMBL-EBI at the 2nd EMBO Conference on Visualizing Biological Data (VIZBI 2014, Heidelberg, March 5-7). The abstract and image of the poster, titled “Visualize signalling to maximize understanding of multiple sclerosis”, can be consulted at:

    Link to original reference 11/08/2014 17:35:11
  • - The CombiMS Patient recruitment and sample collection completed successfully

    The clinical centres involved in CombiMS have completed the recruitment of the MS patients and healthy controls for the study. A total of 255 individuals, counting both MS patients and healthy controls, have been recruited jointly by all the clinical groups involved in the CombiMS consortium (University of Zurich in Switzerland, Karolinska Institute in Sweden, Charité in Berlin and IDIBAPS in Spain). Of these individuals, 26.7 % are healthy controls, 58.6 % are patients with relapsing-remitting MS (RRMS) and 14.7 % are patients with primary progressive MS (PPMS). The consortium has also now completed the collection of samples from these MS patients and healthy control, which was carried out over a 4 month period. All clinical centres have uploaded the clinical information to the secure patient database that is now closed.

    05/08/2014 9:17:49
  • - CombiMS Consortium work presented at the International Conference on Systems Biology of Human Disease

    The work of the CombiMS Consortium was presented by ProtATonce at the International Conference on Systems Biology of Human Disease in Boston (June 17-19, 2014), where it was well received. The abstract of the poster, titled Construction of a drug-induced phosphoprotein/cytokine dataset in clinical samples for Multiple Sclerosis was published the Conference Programme Book (see pages 75-76 containing the abstract in the image to the left). Out of a total of 112 posters, this abstract was among the 12 selected to be presented as a 5' talk on the main stage, where Theodore Sakellaropoulo from ProtATonce had the chance to deliver an oral presentation to an expert audience.

    27/06/2014 11:48:34
  • - The fourth CombiMS meeting was held on the 27th May 2014

    The fourth meeting of the CombiMS Consortium was held at the EMBL-EBI in Hinxton (UK) on the 27th of May, 2014. During the meeting the members of the Consortium took stock of the work carried out during the first half of 2014 and discussed the activities to be undertaken in the next stage of the project to keep on the work plan schedule. The models developed to refine our understanding of Multiple Sclerosis (MS) and the combination therapies available have already been defined and the collection of samples from patients has been completed. With this specific information regarding MS available, the next steps are to fit the models to the experimental data and to validate the model's results. During the meeting, a Keynote lecture on Signalling in T cells was presented by Dr Balbino Alarcon from the Centro de Biologia Molecular Severo Ochoa (CBMSO) and a member of the Scientific Advisory Board (SAB) who also provided the CombiMS consortium with his recommendations on the progress and future activities of the consortium.

    04/06/2014 11:32:58
  • - Technicians Workshop

    A technicians Workshop was hosted by the group of Friedemann Paul at Charité (Berlin) on 26th September in Berlin to train the representatives from each clinical centre involved in the CombiMS consortium in how to isolate the cells from the blood obtained from healthy controls and MS patients from blood samples. The purpose of the workshop was to make sure that all the clinical groups (University of Zurich in Switzerland, Karolinka Institute in Sweden, Charité in Berlin and IDIBAPS in Spain) follow a standardized protocol in order to ensure quality assurance in the experimental procedures for the phosphoproteome and cytokine assays. In this regard all participants successfully completed the workshop. In addition, the workshop ensured that there was a representative in each clinical centre who was familiar with the use of the kit that has been prepared to stimulate the cells obtained, and how these samples should be stored and shipped for analysis.

    01/04/2014 12:42:24
  • - Preparation of kits for the stimulation of cells isolated from MS patients

    ProtATonce has developed a kit that contains all the reagents and materials necessary (tubes, buffers, stimuli, plates, etc) for the clinical centres participating in CombiMS to stimulate the cells isolated from MS patients (and healthy controls) and to prepare and store the samples for shipping. The reagents have been prepared from a single batch to ensure the assays are uniform and their stability over 3 months has been assessed as part of the quality control. The goal is to reduce the variability in the results as much as possible by using the exact same reagents and consumables at each centre. They have prepared 300 kits that have been sent to the four clinical centres participating in the Consortium (Karolinska Institute in Sweden, IDIBAPS in Spain, Charité in Germany and University of Zurich in Switzerland. The kits will be used to obteain both the phosphoproteomic and genotyping data once the cells have been collected at these clinical centres.

    01/04/2014 12:39:53
  • - Third CombiMS Consortium Meeting

    The Third Meeting of the CombiMS Consortium will be held at ProtATonce Headquarters in Athens on the 20th and 21st of January, 2014. ProtATonce is part of the transnational Consortium, led by the Spanish Biopharma company Bionure. During the meeting the members of the Consortium will take stock of the work carried out during the second half of 2013 and discuss the work plan for the next six months. (This meeting is Not open to the general public)

    14/01/2014 12:27:41
  • - A succesful CombiMS meeting closed on the 18th june 2013

    Tuesday the 18th of June saw the close of the 2nd meeting of the CombiMS consortium held at the Centre for Molecular Medicine of the Karolinska Institutet, home to two of the groups participating in the consortium. During the meeting a review of the work carried out to date served to reflect the progress made in the project and that the studies proposed are being completed within the schedule proposed. The assays that needed to be established are now available and good progress has been made in defining the appropriate models that will used to refine our understanding of this disease, and ultimately of the therapeutic options available. In addition, bringing the consortium together at the meeting allowed several important issues regarding the forthcoming work to be discussed, taking important decisions as how best to proceed. It is anticipated that having laid down the foundations, samples from patients can begin to be collected over a 4 month period from September until January 2014, which will provide the specific information regarding MS available to the consortium.

    01/07/2013 12:36:22
  • 12/06/2013 - Second CombiMS Consortium Meeting

    The Second Meeting of the CombiMS Consortium will take place at the Karolinska Institute in Stockholm on June 17-18, 2013. Two research groups from the KI participate in the Consortium, led by the Spanish Biopharma company Bionure. The goal of the Consortium is to develop a novel drug discovery method based on System Biology and apply this to identify a novel combination therapy and biomarkers for Multiple Sclerosis. During the meeting the members of the Consortium will take stock of the work carried out in the first six months of the project and programme that to be carried out in the following six months. (This meeting is Not open to the general public)

    12/06/2013 11:40:46
  • 01/01/2013 - CombiMS, a novel drug discovery method based on systems biology

    CombiMS - A novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis

    Link to original reference 28/02/2013 13:34:18
  • 01/01/2013 - CombiMS, a novel drug discovery method based on systems biology

    CombiMS - A novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis

    Link to original reference 28/02/2013 13:33:47
  • 26/07/2012 - La Unión Europea ha aprobado la creación de CombiMS

    La Unión Europea ha aprobado la creación de CombiMS, un proyecto europeo para desarrollar un nuevo método basado en la biología de sistemas para mejorar el proceso de descubrimiento de fármacos.

    Link to original reference 28/02/2013 12:36:55


TO DOWNLOAD MORE INFO ABOUT COMBIMS

GENERAL INFO


SCIENTIFIC INFO

CONTACT

Albert G. Zamora, Coordinator
Bionure Farma S.L.
Dalmases, 27, Local 1 08017 Barcelona
combims@bionure.com

CombiMS welcomes any questions or comments you might have.
Your questions are important to us, and we will reply as soon as possible.